219 related articles for article (PubMed ID: 15872360)
1. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
Vallabhajosula S; Goldsmith SJ; Kostakoglu L; Milowsky MI; Nanus DM; Bander NH
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
Vallabhajosula S; Kuji I; Hamacher KA; Konishi S; Kostakoglu L; Kothari PA; Milowski MI; Nanus DM; Bander NH; Goldsmith SJ
J Nucl Med; 2005 Apr; 46(4):634-41. PubMed ID: 15809486
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
5. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
6. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
7. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
[TBL] [Abstract][Full Text] [Related]
8. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
10. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
[TBL] [Abstract][Full Text] [Related]
12. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts.
DeNardo GL; Kroger LA; Meares CF; Richman CM; Salako Q; Shen S; Lamborn KR; Peterson JJ; Miers LA; Zhong GR; DeNardo SJ
Clin Cancer Res; 1998 Oct; 4(10):2483-90. PubMed ID: 9796981
[TBL] [Abstract][Full Text] [Related]
14. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
15. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
16. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
[TBL] [Abstract][Full Text] [Related]
17. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
18. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
Breitz HB; Fisher DR; Wessels BW
J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
Colnot DR; Wilhelm AJ; Cloos J; Roos JC; de Bree R; Quak JJ; Snow GB; van Dongen GA
J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
[TBL] [Abstract][Full Text] [Related]
20. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
Pandit-Taskar N; O'Donoghue JA; Morris MJ; Wills EA; Schwartz LH; Gonen M; Scher HI; Larson SM; Divgi CR
J Nucl Med; 2008 Jul; 49(7):1066-74. PubMed ID: 18552139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]